Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lerdelimumab
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
Lerdelimumab is a human monoclonal antibody developed as an immunosuppressive agent targeting transforming growth factor beta 2 (TGF beta 2). Its primary mechanism of action is the inhibition of TGF beta 2, a cytokine involved in fibrotic processes. Lerdelimumab was investigated for reducing scarring after glaucoma drainage surgery and showed potential activity in other ocular diseases such as cataract, retinopathy, and connective tissue diseases. The drug was granted European orphan drug status for preventing scar formation post-glaucoma surgery but development was discontinued after unsuccessful clinical trial results[1][3][6][8].
- Brand names
- Trabio
- Other names
- lerdelimumab
02
Targets
TGFB2 (Transforming growth factor beta 2)
Beyond the preview
Go deeper on lerdelimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lerdelimumab.